Obesity Pipeline Review, H1 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Obesity - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

Obesity - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Obesity (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Obesity (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Obesity and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 18, 28, 1, 120, 32 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 53 and 10 molecules, respectively.

Obesity (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Obesity - Overview
  3. Obesity - Therapeutics Development
  4. Obesity - Therapeutics Assessment
  5. Obesity - Companies Involved in Therapeutics Development
  6. Obesity - Drug Profiles
  7. Obesity - Dormant Projects
  8. Obesity - Discontinued Products
  9. Obesity - Product Development Milestones
  10. Appendix

Companies Mentioned

  • Abeome Corp
  • Arrowhead Pharmaceuticals Inc
  • AstraZeneca Plc
  • Biozeus
  • Boehringer Ingelheim GmbH
  • Braasch Biotech LLC
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Eternygen GmbH
  • FibroGen Inc
  • Genmedica Therapeutics SL
  • Gila Therapeutics Inc
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Lead Discovery Center GmbH
  • Leading BioSciences Inc
  • Magnus Life Ltd
  • MedImmune LLC
  • Merck & Co Inc
  • Novartis AG
  • Novo Nordisk AS
  • Palatin Technologies Inc
  • Peptron Inc
  • Pfizer Inc
  • PharmaIN Corp
  • Poxel SA
  • ProMetic Life Sciences Inc
  • Regeneron Pharmaceuticals Inc
  • Renova Therapeutics Inc
  • Reviva Pharmaceuticals Inc
  • Saniona AB
  • Sanofi
  • Zafgen Inc
  • Zealand Pharma AS

For more information about this report visit https://www.researchandmarkets.com/research/j59j34/obesity_pipeline?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Anti-Obesity Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Anti-Obesity Drugs